Table 1 Clinicopathological profiles of the patients treated with NACT
Characteristic | |||
|---|---|---|---|
Age | 54.15 ± 10.747 | ||
< 40 | 14 | 10.5% | |
> 40 | 119 | 89.5% | |
No menopause | 49 | 36.8% | |
Menopause | 84 | 63.2% | |
T1 | 20 | 15.0% | |
T2 | 80 | 60.2% | |
T3 | 26 | 19.5% | |
T4 | 7 | 5.3% | |
N0 | 36 | 27.1% | |
N1 | 27 | 20.3% | |
N2 | 32 | 24.1% | |
N3 | 38 | 28.6% | |
Stage I | 9 | 6.8% | |
Stage II | 46 | 34.6% | |
Stage III | 78 | 58.6% | |
HR+ | 88 | 66.2% | |
HR- | 45 | 33.8% | |
Her-2 positive | 17 | 12.8% | |
Her-2 negative | 116 | 87.2% | |
TNBC vs | 28 | 21.1% | |
No TNBC | 105 | 78.9% | |
Recurrence VS | 24 | 18.0% | |
No recurrence | 109 | 82.9% | |
CR | TEC | 71 | 53.4% |
EC | 23 | 17.3% | |
TC | 12 | 9.0% | |
TX | 27 | 20.3% | |
Post-NACT neutrophils | 2.92 ± 1.72 | ||
Post-NACT lymphocyte | 1.30 ± 0.48 | ||